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Innate and adaptive immune systems have important role in the pathogenesis of acute and chronic infection with hepatitis B
virus (HBV). These immune responses are mediated through complex interactions between the innate immune response and
adaptive immune response. Toll-like receptors (TLRs) are a family of innate immune-recognition receptors that recognize the
molecular patterns associated with microbial pathogens. So far, TLR1 to 13 were found in human or mice and investigated to
detect the target molecules and the downstream mechanisms of these unique systems. Stimulation by their ligands initiates the
activation of complex networks of intracellular signaling transduction and innate and adaptive immune-related cells (NK, NK-T,
monocytes, dendritic cells, T cells, B cells, and Tregs, etc.). However, reports on such relationships between HBV and TLRs have
been relatively rare in comparison to those on HCV and TLRs, but have recently been increasing. Thus, a review of TLRs involved
in the pathogenesis of HBV infection may be needed toward better understanding of the immunopathogenesis of HBV infection.
1.Introduction
HBV is an enveloped, double-strand DNA virus that causes
acute,chronichepatitisandhepatocellularcarcinoma(HCC)
[1]. HBV infection continues to be a signiﬁcant global health
problem. There are approximately 400 million chronic HBV
carriers in the world, and in approximately 5% of adults and
95% of neonates who become infected with HBV, persistent
infection develops [2].
It has been shown that the innate immune system in-
cluding natural killer (NK) cells, NK-T cells, monocytes, and
intrahepatocyte-immunereactioninadditiontotheadaptive
immune system including cytotoxic T lymphocyte (CTLs),
Th1 CD4+ cells, CD4+CD25+FOXP3+ regulatory T cells
(Tregs), and dendritic cells (DCs) plays an important role
in the control of virus [3–8]. The hyporesponsiveness of
NK cells, HBV-speciﬁc Th1 cells and distortion in regulatory
functions of Tregs have been demonstrated in CHB patients
[9, 10]. Lamivudine treatment in CHB has been reported to
restore both CD4+ and CTL hyporesponsiveness following
the decline of serum levels of HBV-derived Ag by many
groups including us [11]. However, the other group reported
that this restoration of T-cell response might be transient
[12]. We could not conclude whether the reduction of
hepatitis B viral antigens could contribute to the better
response of immune therapy. We previously reported that
HBcAg-speciﬁc IL10 secreting Tregs could have important
roles in the pathogenesis of CHB [13]. More recently, we
found that one of the stress-related proteins produced by
HBV-replicating hepatocytes could enhance the suppressive
activity of Tregs via TLR2 [14]. In addition, HBV antigens
and proteins related to HBV replication were reported to
contribute to the TLR-related immune reactions [15].
TLRs are the most common groups among the pattern
recognition receptors (PRRs), which diﬀer from antigen-
speciﬁc receptors in a number of ways. The TLRs were
initially identiﬁed based on homology with the toll receptor
from Drosophila. They are expressed on many kinds of
cells including hepatocytes and eﬀector cells of the innate
immune and adaptive immune systems. Thus, TLRs might
contribute not only to the innate immune systems but also
to the adaptive immune systems. TLRs can be classiﬁed into
two groups based on subcellular localization. The ﬁrst group
includes TLR1, 2, 4, 5, 6, 11, and 12, which are present2 Gastroenterology Research and Practice
Table 1: TLR signaling aﬀecting the immunopathogenesis of HBV infection.
TLRs Localization Ligand/Pathogen-associated
molecular pattern Contribution to the pathogenesis of HBV infection
TLR1 Plasma membrane Triacyl lipopeptides, soluble
factors Ligand of TLR1 might suppress HBV replication
TLR2 Plasma membrane Lipoprotein/lipopeptide
TLR2 expressions on monocytes and hepatocytes were
reduced in HBeAg+ CHB
sHSP60 produced from HBV-replicating hepatocyte
enhanced Tregs activity via TLR2
HBeAg suppresses activation of the TLR2 signaling
TLR3 Endosomes Double-strand RNA
HBV polymerase inhibits RIG-I- and TLR3-mediated beta
interferon induction
Ligand of TLR3 might suppress HBV replication
Moderate adjuvant function
TLR4 Plasma membrane LPS, fusion protein
Polymorphisms of TLR4 gene may be related to protection
from HBV recurrence after liver transplantation
Ligand of TLR4 might suppress HBV replication via CTL
activation
TLR5 Plasma membrane Flagellin Moderate adjuvant function
TLR6 Plasma membrane Diacyl lipopeptides
TLR7 Endosomes single-strand RNA Moderate adjuvant function
TLR8 Endosomes Imidazoquinolne, single-strand
RNA
TLR9 Endosomes CpG DNA Strongly enhances CTL activation; HBV vaccine with TLR9
ligand might be eﬀective
TLR11 Plasma membrane Proﬁlins-like protein
TLR12 Plasma membrane not clear
TLR13 Vesicular stomatitis virus
at plasma membrane (Table 1). The second group includes
TLR3, 7, 8, and 9, which localize to intracellular compart-
m e n t ss u c ha se n d o s o m e s[ 16]. Once the TLRs recognize
a pathogen-associated molecular pattern, the eﬀector cell is
triggered to perform its function immediately, rather than
after proliferation in the lymph nodes. Stimulation is started
through the involvement of adaptor protein MyD88, protein
kinase, and the transcription factor, nuclear factor kappa B
(NF-κB), which can induce a variety of cytokines including
TNF-α, IL-1, and IL-6. Thereafter, stimulation of TLRs could
contribute to the coordination of inﬂammatory immune
responses. So far, TLR2, 3, 4, 7, 8, and 9 might have roles in
thepathogenesisofvariouskindsofviralinfectionsincluding
hepatitis B and C (Table 1).
2.TLRs andHBV Replicating Hepatocyte
The initial step of the innate immune response is induced by
type 1 IFN secretion from infected hepatocytes via stimula-
tion of TLRs in hepatitis C virus infection [17, 18]. However,
the relationship between HBV and TLRs in hepatocyte has
been relatively unclear in comparison to that between HCV
andTLRs.It has beenreported that the expression ofTLR2is
regulated by the precore protein in CHB, and that there was
signiﬁcantly reduced cytokine production (TNF-alfa) and
phospho-p38 kinase expression in the presence of HBeAg
[19]. More recently, the same group reported that HBeAg
colocalized with the Toll/IL-1-receptor-(TIR-) containing
proteinsTRAM,MAL,andTLRatthesubcellularlevel.Thus,
HBeAg was able to disrupt TIR:TIR interaction critical for
TLR-mediated signaling [20]. Another group reported that
HBV polymerase might inhibit IFN-beta expression at the
TBK/IKKe level. IFN-beta induction is one of the ﬁrst-phase
characteristics of the activation of the type I IFN system [21].
In addition to these reports, other groups have described
that HBV could suppress TLRs signaling in hepatocytes as
well as nonparenchymal liver cells [22]. These reports were
very important, since direct disruption of TLRs signaling
was demonstrated in CHB patients as seen in CHC patients
(Figure 1). For example, HCV NS3/4A could cleave TRIF
and IPS-1 and lead to a deﬁciency of IFN-beta induction
in HCV-infected hepatocytes [18]. Not only TLRs but also
retinoic acid-inducible gene I (RIG-I) might be involved in
thepathogenesisofHBVinfection.Kumaretal.reportedthat
HBx protein (the 17kDa HBV regulatory protein that plays
an essential role in virus replication) could bind to adaptor
proteinIPS-1andinhibitthedsDNA-inducedIFN-beta[23].Gastroenterology Research and Practice 3
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Figure 1: TLRs contribution to Hepatocellular- and monocyte-related immune systems.
3. TLRs Expressionon Monocytes andDCs
in HBV Infection
Monocytes including Kupﬀer cells play an important role
in mediating the innate and adaptive immune responses.
Various kinds of TLRs are highly expressed on monocytes
in comparison to NK cells and CD3+ lymphocytes. It was
reported that TLR2 expressions on peripheral monocytes
were reduced in patients with HBeAg+ CHB [24]. In addi-
tion to the TLR2 expression, another group clearly demon-
strated that the cytokine induction by the HBV capsid in
macrophages is facilitated by the interaction of its arginine-
rich domain with membrane heparan sulfate and involves
signaling through TLR2. They found the mechanisms of
cytokine induction by HBV core Ag (HBcAg), which serves
as the structural subunit of the highly immunogenic capsid
shell. HBcAg harbors a unique arginine-rich C terminus that
has been implicated in the immune responses induced by the
capsid[15].Althoughithasalsobeenreportedthatnoquan-
titative, phenotypic of functional impairment of mDCs or
pDCs was found in CHB [25], TLR3/IFN-beta signaling was
decreased signiﬁcantly in mDCs from patients with chronic
hepatitis B or acute-on-chronic hepatitis B liver failure, com-
pared with normal controls [26]( Figure 1). Moreover, the
existence of a relationship between TLR2/4 expressions on
monotyes and Tregs in CHB patients was reported recently
[27]( Figure 2). In addition to TLR2/4, impairment of TLR7
and TLR9 signaling might be associated with chronic viral
infection including HIV-1, HBV, and HCV. One group
reportedthatvirusesandcomponentsofthetumormicroen-
vironment interact with regulatory receptors on plasmacy-
toid dendritic cells to impair TLR7 and TLR9 signaling.4 Gastroenterology Research and Practice
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Figure 2: TLRs contribution to PBMC, CD3+/CD4+/CD8+ T cells, and Tregs-related immune systems.
4. TLRsExpressiononPBMC,
CD3+/CD4+/CD8+TCells,andTregsin
HBV Infection
For the resolution of viral infection, the eﬃcient recognition
of intracellular viruses is essential. It has been reported that
CTLs and Th1 play a central role in the control of viral
infection after the rapid response by NK and NK-T cells [4].
CTL recognizes viral antigens synthesized within infected
cells in the form of oligopeptides that are presented on HLA
class I molecules. Many groups including us have reported
on the hyporesponsiveness of HBV-speciﬁc CTLs in the
peripheral blood of patients with CHB [11, 28–30]. There
may be several mechanisms in this CTLs hyporesponsiveness
including anergy, exhaustion induced by the large amount
of HBV antigens, PD-1: PD-L1 interaction, and excessive
function of Tregs during CHB [3, 11, 13, 14, 31–36]. Among
these immune cells that could contribute to the cellular
immune responses, the involvement of Tregs was investi-
gated intensely [13, 14, 27, 34–41]. However, although the
expression levels of TLRs were relatively low in comparison
to monocytes and DCs, the biological signiﬁcance of TLRs
expression on a variety of T cells was substantial [27, 34, 36–
44]. It has been shown that TLR2 and 4 were important
for the regulation of Tregs [42–44]. More recently, we have
shownthatthesolubleformofheatshockprotein60induced
by HBV-replicating hepatocytes could enhance the HBcAg-
speciﬁc Il10 secreting activity of Tregs via TLR2 (Figure 2).
The suppression of HBV replication with entecavir therapy
could reduce the excessive function of Tregs in CHB [14].
Based on other ﬁndings and those of our studies, not only
the HBV antigens but also unknown proteins produced from
HBV-replicating hepatocytes and other cells could aﬀect the
immune function via TLRs.
5. Immunological Therapy withTLR Agonist
Interferon and nucleos(t)ide analogs, such as lamivudine,
adefovir, entecavir, and tenofovir, are the currently available
treatments. Interferon-alfa is eﬀective in approximately 30%
of cases and even less so in younger cases [45]. The eﬃcacy
of nucleos(t)ide analogs is limited by viral reactivation
because of the emergence of escaped mutants in cases of
prolonged treatment [46, 47]. Immunotherapy is one of theGastroenterology Research and Practice 5
important options to control HBV replication. Various kinds
of immune therapies including protein vaccines, DNA vac-
cine, T-cell epitope vaccines, and immunomodulating agents
(cytokines, IFN, and TLR agonists) have been reported [48–
51].
So far, a promising immune therapy that could eradicate
or control HBV has not been developed. Cellular immune
responses are suppressed by various kinds of mechanisms.
Therefore, TLR agonists were strong candidates to activate
and modulate the impaired immune responses with HBV
epitopes, proteins, and DNA vaccines [52–57]. Whether
TLR2, 3, 4, 5, 7, and 9 signaling could enhance the CTL
response upon vaccination has been examined. The results
indicated that TLR2 and 4 failed to increase the CTL
response, whereas stimulation by TLR3, 5, and 7 exhibited
a moderate adjuvant function. In contrast, stimulation of
TLR9 dramatically increased the CTL responses [54]. On
the other hand, TLR4 in addition to TLR 3, 5, 7, and 9
was reported to have the ability to suppress HBV replication
in a mouse model [52, 53]. Thereafter, a vaccine based on
HBV antigens and immunostimulatory DNA sequence, an
adjuvant that acts as a TLR9 agonist, was developed [55].
However, to determine the potential of using TLR agonists to
improve the HBV-speciﬁc immune response, future studies
will be needed.
6. Concluding Remarks
Recently various studies about the immunopathogenesis
of HBV infection, including adaptive and innate immune
responses, have been reported, and the contribution of TLRs
signaling to the pathogenesis of HBV infection is receiving
increasedinterest.Inthispaper,wedescribedthesuppression
of TLRs signaling in heptocytes and immune cells during
HBV infection, however, reports concerning the suppression
of TLRs signaling in HBV infection have been few in
comparison to those on HCV infection. The involvement of
TLRs signaling suppression during HBV persistent infection
should be considered more precisely. For example, the
relationship between HBV genotypes and the level of TLRs
suppressionisnotclearyet.Asforimmunetherapy,theTLRs
agonists, especially TLR9 agonist, with various kinds of HBV
vaccines could be strong candidates to activate the HBV-
speciﬁc immune responses that are suppressed during HBV
persistent infection. The combination of TLR agonists and
appropriately timed immune therapy should be considered
in future studies.
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